Podrid P J
Section of Cardiology, Boston University School of Medicine, Massachusetts.
J Cardiovasc Pharmacol. 1992;20 Suppl 2:S44-58.
The present article reviews the therapeutic efficacy of class III antiarrhythmic agents, particularly amiodarone, in patients with atrial and ventricular arrhythmias in the setting of different cardiac disorders. Both Holter monitoring and electrophysiologic studies appear to constitute reliable methods for evaluating the effects of class III agents and the long-term outcome in patients with a history of sustained ventricular tachycardia or fibrillation. The efficacy and tolerance of amiodarone in different patient populations is discussed.